Real-world immune-related adverse events in patients with early triple negative breast cancer who received pembrolizumab. Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in ...
SUPRAME: A phase 3 trial comparing IMA203, an engineered T-cell receptor expressing T cell therapy (TCR-T) vs investigator’s choice in patients with previously treated advanced cutaneous melanoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results